二甲双胍对2型糖尿病患者肠道微生物的调控谱:基于1431名参与者的个体水平Meta分析
该研究基于9个数据集、1431名参与者的个体水平Meta分析,系统评估二甲双胍对2型糖尿病患者肠道微生物的影响。结果显示二甲双胍显著增加Akkermansia及产短链脂肪酸菌(如Pseudobutyrivibrio、Oribacterium、Anaerotruncus),同时减少致病菌(如Enterobacillus、Gemmobacter、Shinella、Klebsiella、Enterocloster);Bifidobacterium和Blautia在T2D患者中升高,二甲双胍使其恢复至接近正常水平,且该变化具有区域特异性。
要点
- 二甲双胍显著增加Akkermansia及产短链脂肪酸菌(Pseudobutyrivibrio、Oribacterium、Anaerotruncus)。
- 二甲双胍同时减少致病菌(Enterobacillus、Gemmobacter、Shinella、Klebsiella、Enterocloster)。
- Bifidobacterium和Blautia在T2D患者中升高,二甲双胍使其恢复至接近正常水平,且变化具区域特异性。
核心结论
- 该分析为二甲双胍治疗后肠道微生物群的变化提供了更具体的证据,丰富了对肠道微生物动态与2型糖尿病管理之间相互作用的理解。
研究设计与样本
- 个体水平Meta分析,检索7个数据库(自建库至2024年10月30日),从NCBI下载9个可用数据集的原始序列读段,最终纳入1431名参与者。
- 文献筛选与评估由2名作者独立完成,数据提取采用标准化表格。
主要发现
- 二甲双胍显著增加Akkermansia及产短链脂肪酸菌(如Pseudobutyrivibrio、Oribacterium、Anaerotruncus)的丰度。
- 二甲双胍同时减少致病菌(包括Enterobacillus、Gemmobacter、Shinella、Klebsiella、Enterocloster)的丰度。
- Bifidobacterium和Blautia在2型糖尿病患者中升高,二甲双胍使其恢复至接近正常水平,且该变化具有区域特异性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The gut microbiota plays a significant role in metformin efficacy and therapeutic response. However, studies often have produced inconsistent outcomes. OBJECTIVE: To gain a more comprehensive understanding of the transformation of gut microbiota in persons with diabetes and the subsequent modifications following metformin intervention. DATA SOURCES: Seven databases were searched, from the inception of each database up to October 30, 2024. The raw sequence reads of 9 available datasets were downloaded from the National Center for Biotechnology Information (NCBI). STUDY SELECTION: The process of selecting and assessing papers for this study was meticulously managed by 2 authors, working independently to screen and evaluate each publication. DATA EXTRACTION: For the data extraction phase, a standardized form was employed, capturing critical details. DATA SYNTHESIS: Metformin significantly boosts the presence of Akkermansia and short-chain fatty acid (SCFA)-producing bacteria, such as Pseudobutyrivibrio, Oribacterium, and Anaerotruncus, and it simultaneously diminishes pathogenic bacteria, including Enterobacillus, Gemmobacter, Shinella, Klebsiella, and Enterocloster. In addition, Bifidobacterium and Blautia were increased in patients with type 2 diabetes (T2D) but restored to near normal levels by metformin, and this alteration is region-specific. CONCLUSION: Our analysis delivers more concrete evidence regarding the shifts in gut microbiota following metformin treatment, significantly enriching our understanding of the interplay between gut microbiome dynamics and the management of T2D.
引用
- Su W, Yang Y, Cheng J, et al. The Microbial Regulation Spectrum of Metformin in Patients With Type 2 Diabetes: An Individual-Based Meta-Analysis of 1431 Participants. J Clin Endocrinol Metab. 2025. PMID: 40233167. doi:10.1210/clinem/dgaf238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。